Opinion|Videos|April 7, 2025
Post-Imatinib Progression: Decision Factors and Treatment Options
Experts discuss key factors influencing decision-making when patients with advanced gastrointestinal stromal tumors (GIST) progress on imatinib, reviewing standard second-line options, considerations for increasing imatinib dosing vs switching to a different tyrosine kinase inhibitor (TKI), and clinical or radiographic patterns that guide therapy changes or dose escalation at progression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With imatinib as our established first-line therapy for advanced GIST, what key factors influence your decision-making when patients progress? What are our standard second-line options, and what factors influence this treatment selection?
- What specific clinical or molecular factors would lead you to consider increasing imatinib dosing rather than switching to a different TKI?
- What specific clinical or radiographic patterns at the time of progression signal would definitively guide you to switch therapies vs dose escalation?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5